Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples